Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by First Trust Advisors LP

Key Points

• First Trust Advisors LP increased its stake in Regeneron by 7.7% in Q3, adding 14,213 shares to hold 198,257 shares worth about $111.5 million, while institutional investors own roughly 83.31% of the company.
• Regeneron beat quarterly estimates with EPS of $11.44 (vs. $10.74) and revenue of $3.88 billion (vs. $3.76 billion), and raised its quarterly dividend to $0.94 (annualized $3.76).
• Several analysts have lifted targets—Evercore, Guggenheim and Oppenheimer raised theirs to $875, $975 and $865 respectively—leaving a MarketBeat consensus of Moderate Buy and an average target of $802.27.

First Trust Advisors LP raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 198,257 shares of the biopharmaceutical company's stock after acquiring an additional 14,213 shares during the quarter. First Trust Advisors LP owned approximately 0.19% of Regeneron Pharmaceuticals worth $111,474,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. DCF Advisers LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 6.4% in the third quarter. DCF Advisers LLC now owns 10,000 shares of the biopharmaceutical company's stock valued at $5,623,000 after purchasing an additional 600 shares in the last quarter. Intellectus Partners LLC raised its position in shares of Regeneron Pharmaceuticals by 3.5% during the 3rd quarter. Intellectus Partners LLC now owns 2,743 shares of the biopharmaceutical company's stock worth $1,542,000 after purchasing an additional 93 shares during the last quarter. Gamco Investors INC. ET AL raised its position in shares of Regeneron Pharmaceuticals by 7.3% during the 3rd quarter. Gamco Investors INC. ET AL now owns 646 shares of the biopharmaceutical company's stock worth $363,000 after purchasing an additional 44 shares during the last quarter. Pitcairn Co. lifted its stake in Regeneron Pharmaceuticals by 102.9% in the 3rd quarter. Pitcairn Co. now owns 968 shares of the biopharmaceutical company's stock valued at $544,000 after buying an additional 491 shares in the last quarter. Finally, Crossmark Global Holdings Inc. lifted its stake in Regeneron Pharmaceuticals by 1.9% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 2,308 shares of the biopharmaceutical company's stock valued at $1,298,000 after buying an additional 42 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the business's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares in the company, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the company's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the transaction, the senior vice president directly owned 4,272 shares of the company's stock, valued at $3,325,837.44. This trade represents a 32.28% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 5,274 shares of company stock worth $4,142,738. 7.02% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on REGN shares. Evercore raised their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an "outperform" rating in a research report on Thursday, January 22nd. HSBC started coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They issued a "buy" rating and a $255.00 price objective on the stock. Scotiabank lifted their price objective on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a "sector perform" rating in a research report on Monday, November 24th. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a "buy" rating in a research note on Monday, February 9th. Finally, Oppenheimer restated an "outperform" rating and issued a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $802.27.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $759.82 on Monday. The stock has a market capitalization of $80.33 billion, a price-to-earnings ratio of 18.28, a price-to-earnings-growth ratio of 2.04 and a beta of 0.40. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The stock's fifty day simple moving average is $770.81 and its 200-day simple moving average is $689.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the firm posted $12.07 earnings per share. The business's quarterly revenue was up 2.5% compared to the same quarter last year. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were paid a dividend of $0.94 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is an increase from Regeneron Pharmaceuticals's previous quarterly dividend of $0.88. Regeneron Pharmaceuticals's dividend payout ratio is currently 9.05%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.